The FDA must approve any GLP-1 receptor agonist (e.g., semaglutide, tirzepatide, or similar) for over-the-counter sale without a prescription before January 1, 2028. Based on official FDA approval announcements.
Sign in to make predictions, track your accuracy, and compete on the leaderboard.
Sign in to predictNo comments yet. Be the first to share your reasoning.
Sign in to join the discussion